MX2022004257A - Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales. - Google Patents

Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.

Info

Publication number
MX2022004257A
MX2022004257A MX2022004257A MX2022004257A MX2022004257A MX 2022004257 A MX2022004257 A MX 2022004257A MX 2022004257 A MX2022004257 A MX 2022004257A MX 2022004257 A MX2022004257 A MX 2022004257A MX 2022004257 A MX2022004257 A MX 2022004257A
Authority
MX
Mexico
Prior art keywords
cannabidiol
cbd
treatment
seizure disorders
transdermal compositions
Prior art date
Application number
MX2022004257A
Other languages
English (en)
Inventor
Marina Borovinskaya
Nisarg Modi
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2022004257A publication Critical patent/MX2022004257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente descripción se refiere a la administración transdérmica de cannabidiol (CBD) para la reducción de la frecuencia de las convulsiones en el tratamiento de la "epilepsia resistente al tratamiento" (TRE).
MX2022004257A 2019-10-11 2020-10-08 Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales. MX2022004257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913874P 2019-10-11 2019-10-11
PCT/IB2020/059482 WO2021070120A1 (en) 2019-10-11 2020-10-08 Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders

Publications (1)

Publication Number Publication Date
MX2022004257A true MX2022004257A (es) 2022-05-26

Family

ID=75438036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004257A MX2022004257A (es) 2019-10-11 2020-10-08 Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.

Country Status (8)

Country Link
US (1) US20210113489A1 (es)
EP (1) EP4041209A4 (es)
JP (1) JP2022551696A (es)
CN (1) CN114555067A (es)
AU (1) AU2020361741A1 (es)
CA (1) CA3155176A1 (es)
MX (1) MX2022004257A (es)
WO (1) WO2021070120A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117479930A (zh) * 2021-04-08 2024-01-30 长矛治疗股份有限公司 用于治疗癫痫发作病症的药物组合物和方法
CN113698802B (zh) * 2021-08-24 2022-04-22 金隅微观（沧州）化工有限公司 一种石墨烯杂化的有机-无机防腐涂料及制备方法
CN116459235B (zh) * 2023-02-21 2024-05-24 四川旅游学院 一种含吡仑帕奈的透皮贴剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
JP5801794B2 (ja) * 2009-04-28 2015-10-28 ジネルバ ファーマシューティカルズ， インコーポレイティド カンナビジオールの製剤及びその使用方法
WO2011026144A1 (en) * 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
MX2020003004A (es) * 2017-09-19 2020-11-06 Zynerba Pharmaceuticals Inc Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.

Also Published As

Publication number Publication date
EP4041209A4 (en) 2024-01-24
WO2021070120A1 (en) 2021-04-15
EP4041209A1 (en) 2022-08-17
JP2022551696A (ja) 2022-12-13
US20210113489A1 (en) 2021-04-22
CN114555067A (zh) 2022-05-27
CA3155176A1 (en) 2021-04-15
AU2020361741A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
MX2019015315A (es) Composiciones y tratamientos para el trastorno del sueño.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2019001285A (es) Composicion de cannabis.
MX2021000814A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2021000020A (es) Composicion y metodo para tratar el dolor.
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MX2019008875A (es) Composiciones de inhibidor del canal crac.
MX2021014158A (es) Uso de cannabidiol en el tratamiento de espasmos epilepticos.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
MX2019014251A (es) Composicion para tratar o prevenir trastornos del climaterio.
MX2022000733A (es) Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos.
WO2020214100A3 (en) Composition
MX2019013897A (es) Composiciones sinergicas que comprenden dimiracetam (r) (1) y dimiracetam (s) (2) en una proporcion no racemica.
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
CA3156118A1 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CYCLOBENZAPRINE
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.